Switch theme
Sign up to access all valuation multiples
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
2006
120
Last FY Revenue $11.7M
Last FY EBITDA $1.5M
$135M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, BrainsWay achieved revenue of $11.7M and an EBITDA of $1.5M.
BrainsWay expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BrainsWay valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $11.7M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 75% | XXX | XXX | XXX |
| EBITDA | XXX | $1.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 13% | XXX | XXX | XXX |
| EBIT | XXX | $0.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $0.8M | XXX | XXX | XXX |
| Net Margin | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BrainsWay's stock price is ILS 19 (or $5).
BrainsWay has current market cap of ILS 705M (or $201M), and EV of ILS 472M (or $135M).
See BrainsWay trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $135M | $201M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BrainsWay has market cap of $201M and EV of $135M.
BrainsWay's trades at 11.5x EV/Revenue multiple, and 88.1x EV/EBITDA.
Equity research analysts estimate BrainsWay's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BrainsWay's P/E ratio is not available.
See valuation multiples for BrainsWay and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $201M | XXX | $201M | XXX | XXX | XXX |
| EV (current) | $135M | XXX | $135M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 88.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 339.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 241.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 72.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBrainsWay's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
BrainsWay's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BrainsWay's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BrainsWay and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BrainsWay acquired XXX companies to date.
Last acquisition by BrainsWay was XXXXXXXX, XXXXX XXXXX XXXXXX . BrainsWay acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BrainsWay founded? | BrainsWay was founded in 2006. |
| Where is BrainsWay headquartered? | BrainsWay is headquartered in Israel. |
| How many employees does BrainsWay have? | As of today, BrainsWay has 120 employees. |
| Who is the CEO of BrainsWay? | BrainsWay's CEO is Mr. Hadar Levy. |
| Is BrainsWay publicy listed? | Yes, BrainsWay is a public company listed on TAE. |
| What is the stock symbol of BrainsWay? | BrainsWay trades under BWAY ticker. |
| When did BrainsWay go public? | BrainsWay went public in 2007. |
| Who are competitors of BrainsWay? | Similar companies to BrainsWay include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of BrainsWay? | BrainsWay's current market cap is $201M |
| Is BrainsWay profitable? | Yes, BrainsWay is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
